Biolipox is a Swedish research-intensive pharmaceutical company in respiratory and inflammatory diseases. The core of Biolipox operations is based on arachidonic acid and its conversion into biologically active substances e.g. prostaglandins and leukotrienes, also called eicosanoids. The company has currently three drug development projects within asthma, allergy and pain aimed at decreasing the formation and/or action of various eicosanoids.
The overall aim with the EICOSANOX project is that increased knowledge about the biological role of eicosanoids and nitric oxide will lead to the identification of novel targets and strategies of significance for the development of new medicines in major disease areas. In the EICOSANOX consortium, Biolipox will provide expertise in drug development, intellectual property management and technology transfer processes.